

# Giovanna Roncador

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7088635/publications.pdf>

Version: 2024-02-01

104  
papers

7,492  
citations

76326

40  
h-index

53230

85  
g-index

105  
all docs

105  
docs citations

105  
times ranked

9556  
citing authors

#	ARTICLE	IF	CITATIONS
1	High <i>PTX3</i> expression is associated with a poor prognosis in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2022, 113, 334-348.	3.9	23
2	Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction. <i>Pharmacological Research</i> , 2022, 179, 105918.	7.1	5
3	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. <i>Human Pathology</i> , 2022, 124, 67-75.	2.0	4
4	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 2154.	3.7	1
5	TOX Expression in Mycosis Fungoides and Sezary Syndrome. <i>Diagnostics</i> , 2022, 12, 1582.	2.6	2
6	Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma. <i>Hemato</i> , 2021, 2, 182-206.	0.6	13
7	High Expression of Caspase-8 Associated with Improved Survival in Diffuse Large B-Cell Lymphoma: Machine Learning and Artificial Neural Networks Analyses. <i>BioMedInformatics</i> , 2021, 1, 18-46.	2.0	14
8	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel. <i>Cancers</i> , 2021, 13, 6384.	3.7	24
9	The Antibody Society's antibody validation webinar series. <i>MAbs</i> , 2020, 12, 1794421.	5.2	26
10	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. <i>PLoS ONE</i> , 2020, 15, e0229743.	2.5	10
11	Title is missing!. , 2020, 15, e0229743.		0
12	Title is missing!. , 2020, 15, e0229743.		0
13	Title is missing!. , 2020, 15, e0229743.		0
14	Title is missing!. , 2020, 15, e0229743.		0
15	Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. <i>Pathology International</i> , 2019, 69, 260-271.	1.3	10
16	High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 1-16.	0.8	36
17	Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 482-485.	1.3	0
18	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. <i>Oncotarget</i> , 2018, 9, 16124-16133.	1.8	30

#	ARTICLE	IF	CITATIONS
19	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients. <i>American Journal of Surgical Pathology</i> , 2018, 42, 936-950.	3.7	26
20	Nkx2-3 "A Slippery Slope From Development Through Inflammation Toward Hematopoietic Malignancies. <i>Biomarker Insights</i> , 2018, 13, 117727191875748.	2.5	12
21	p42 <sup>MAPK</sup> 1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. <i>British Journal of Haematology</i> , 2017, 176, 661-664.	2.5	2
22	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<sc>DLBCL</sc>) reveals gain at 1q31 and <sc>RGS</sc>1 encoding protein; high <sc>RGS</sc>1 immunohistochemical expression associates with poor overall survival in <sc>DLBCL</sc> not otherwise specified (<sc>NOS</sc>). <i>Histopathology</i> , 2017, 70, 595-621.	2.9	41
23	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 465-476.	0.7	7
24	The European antibody network's practical guide to finding and validating suitable antibodies for research. <i>MAbs</i> , 2016, 8, 27-36.	5.2	46
25	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. <i>Oncotarget</i> , 2016, 7, 52940-52956.	1.8	16
26	NOTCH pathway inactivation promotes bladder cancer progression. <i>Journal of Clinical Investigation</i> , 2015, 125, 824-830.	8.2	86
27	Functional and in silico assessment of MAX variants of unknown significance. <i>Journal of Molecular Medicine</i> , 2015, 93, 1247-1255.	3.9	25
28	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0125203.	2.5	30
29	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. <i>PLoS ONE</i> , 2014, 9, e112148.	2.5	18
30	Elevated receptor for activated C kinase 1 expression is involved in intracellular Ca <sup>2+</sup> influx and potentially associated with compromised regulatory T cell function in patients with asthma. <i>Clinical and Experimental Allergy</i> , 2014, 44, 1154-1169.	2.9	10
31	In Response. <i>American Journal of Dermatopathology</i> , 2014, 36, 103.	0.6	0
32	Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia. <i>Nature Communications</i> , 2014, 5, 4226.	12.8	45
33	Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. <i>Human Pathology</i> , 2014, 45, 1730-1736.	2.0	34
34	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. <i>Biomarker Insights</i> , 2014, 9, BMI.S16553.	2.5	7
35	Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour. <i>British Journal of Dermatology</i> , 2013, 169, 1212-1218.	1.5	19
36	BCL7A protein expression in normal and malignant lymphoid tissues. <i>British Journal of Haematology</i> , 2013, 160, 106-109.	2.5	9

#	ARTICLE	IF	CITATIONS
37	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. <i>Blood</i> , 2013, 121, 643-647.	1.4	47
38	p38 $\beta$ limits the contribution of MAP17 to cancer progression in breast tumors. <i>Oncogene</i> , 2012, 31, 4447-4459.	5.9	26
39	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2012, 18, 2828-2837.	7.0	277
40	CD4/CD8 Double Negative Mycosis Fungoides With PD-1 (CD279) Expression: A Disease of Follicular Helper T-Cells?. <i>American Journal of Dermatopathology</i> , 2012, 34, 757-761.	0.6	32
41	RNASSET2: An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. <i>Journal of Proteomics</i> , 2012, 75, 5279-5292.	2.4	9
42	Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCL) while other markers for nodal DLBCL are not useful. <i>Histopathology</i> , 2012, 60, 785-792.	2.9	17
43	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. <i>Nature Genetics</i> , 2011, 43, 663-667.	21.4	478
44	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , 2011, 118, 5517-5527.	1.4	83
45	Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. <i>Immunology Letters</i> , 2011, 134, 150-156.	2.5	8
46	Impaired Ca <sup>2+</sup> Regulation of CD4 <sup>+</sup> CD25 <sup>+</sup> Regulatory T Cells from Pediatric Asthma. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 148-158.	2.1	9
47	A Variety of T-Cell Subsets Contribute to CD4 <sup>+</sup> T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4 <sup>+</sup> and CD4 <sup>+</sup> FoxP3 <sup>+</sup> T-Cell Numbers Predict Clinical Outcome. <i>Blood</i> , 2011, 118, 3684-3684.	1.4	3
48	Participation of Th17 and Treg Cells in Pediatric Bronchial Asthma. <i>Journal of Health Science</i> , 2010, 56, 589-597.	0.9	6
49	Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 234-244.	6.7	593
50	Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. <i>British Journal of Haematology</i> , 2010, 149, 221-230.	2.5	34
51	Proliferation centers in chronic lymphocytic leukemia: the niche where NF- $\kappa$ B activation takes place. <i>Leukemia</i> , 2010, 24, 872-876.	7.2	34
52	A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1 <sup>+</sup> Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages. <i>Clinical Cancer Research</i> , 2010, 16, 637-650.	7.0	151
53	Comparison of Choi and Hans' Algorithms by Immunohistochemistry and Quantitative Reverse Transcriptase-PCR: Letter. <i>Clinical Cancer Research</i> , 2010, 16, 3805-3806.	7.0	1
54	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , 2010, 95, 1342-1349.	3.5	128

#	ARTICLE	IF	CITATIONS
55	Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. <i>Human Pathology</i> , 2010, 41, 1726-1734.	2.0	40
56	Expression pattern of XBP1(S) in human B-cell lymphomas. <i>Haematologica</i> , 2009, 94, 419-422.	3.5	27
57	FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1908-1915.	0.9	41
58	Follicular Tâ€œcell lymphoma: description of a case with characteristic findings suggesting it is a different condition from AITL. <i>Histopathology</i> , 2009, 54, 902-904.	2.9	7
59	Identification of MNDA as a new marker for nodal marginal zone lymphoma. <i>Leukemia</i> , 2009, 23, 1847-1857.	7.2	87
60	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. <i>Modern Pathology</i> , 2009, 22, 753-761.	5.5	65
61	High Numbers of Tumor-Infiltrating Programmed Cell Death 1â€œPositive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1470-1476.	1.6	273
62	Cancer Abolishes the Tissue Type-Specific Differences in the Phenotype of Energetic Metabolism. <i>Translational Oncology</i> , 2009, 2, 138-145.	3.7	53
63	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2009, 33, 81-90.	3.7	226
64	Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 682-690.	3.7	189
65	PIM as a Rational Target for B-Cell Lymphomas.. <i>Blood</i> , 2009, 114, 3946-3946.	1.4	0
66	Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 3953-3953.	1.4	0
67	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. <i>Blood</i> , 2008, 111, 351-358.	1.4	69
68	Peripheral T-cell Lymphoma With Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1787-1799.	3.7	115
69	PD-1, a Follicular T-cell Marker Useful for Recognizing Nodular Lymphocyte-predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1252-1257.	3.7	122
70	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. <i>Blood</i> , 2008, 112, 2815-2815.	1.4	2
71	Generation of a New Monoclonal Antibody Against MALT1 by Genetic Immunization. <i>Hybridoma</i> , 2007, 26, 86-91.	0.4	3
72	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. <i>International Immunology</i> , 2007, 19, 825-835.	4.0	124

#	ARTICLE	IF	CITATIONS
73	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 1059-1066.	3.5	142
74	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. <i>Oncogene</i> , 2007, 26, 1616-1625.	5.9	130
75	Peripheral T-Cell Lymphomas with Follicular Growth Patterns Are Derived from Follicular Helper T Cells (TFH): A Link with Angioimmunoblastic T-Cell Lymphomas?.. <i>Blood</i> , 2007, 110, 3568-3568.	1.4	1
76	Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. <i>Cancer Immunity</i> , 2007, 7, 7.	3.2	107
77	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. <i>Blood</i> , 2006, 107, 213-221.	1.4	39
78	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. <i>Blood</i> , 2006, 108, 2957-2964.	1.4	448
79	Paucity of FOXP3+ cells in skin and peripheral blood distinguishes SÅ©zary syndrome from other cutaneous T-cell lymphomas. <i>Leukemia</i> , 2006, 20, 1123-1129.	7.2	85
80	The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. <i>Leukemia</i> , 2006, 20, 1439-1441.	7.2	46
81	PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. <i>Leukemia</i> , 2006, 20, 2172-2174.	7.2	27
82	Function and recruitment of mucosal regulatory T cells in human chronic <i>Helicobacter pylori</i> infection and gastric adenocarcinoma. <i>Clinical Immunology</i> , 2006, 121, 358-368.	3.2	96
83	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. <i>International Journal of Cancer</i> , 2006, 118, 3161-3166.	5.1	44
84	Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 31-38.	2.5	12
85	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. <i>Haematologica</i> , 2006, 91, 467-74.	3.5	70
86	Differential expression of NF-Î³B pathway genes among peripheral T-cell lymphomas. <i>Leukemia</i> , 2005, 19, 2254-2263.	7.2	112
87	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. <i>Leukemia</i> , 2005, 19, 2247-2253.	7.2	131
88	Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. <i>European Journal of Immunology</i> , 2005, 35, 1681-1691.	2.9	528
89	Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells. <i>Clinical Cancer Research</i> , 2005, 11, 1467-1473.	7.0	401
90	FOXP3 Expression in B and T Cell Lymphomas.. <i>Blood</i> , 2005, 106, 4503-4503.	1.4	0

#	ARTICLE	IF	CITATIONS
91	BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells.. Blood, 2005, 106, 4392-4392.	1.4	0
92	Human BCL11B Is Expressed in Normal T Cells and Differentially Expressed in T-Cell Malignancies.. Blood, 2005, 106, 4393-4393.	1.4	0
93	Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia, 2004, 18, 348-353.	7.2	28
94	Identification of Candidate Oncogenes in Acute Megakaryoblastic Leukemias with Gain of Chromosome 19.. Blood, 2004, 104, 2023-2023.	1.4	0
95	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. Laboratory Investigation, 2001, 81, 419-426.	3.7	158
96	Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. European Journal of Immunology, 2000, 30, 3552-3561.	2.9	186
97	Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. British Journal of Haematology, 2000, 109, 584-591.	2.5	86
98	Detection of Normal and Chimeric Nucleophosmin in Human Cells. Blood, 1999, 93, 632-642.	1.4	101
99	Immunohistochemical screening for oncogenic tyrosine kinase activation. , 1999, 187, 588-593.		14
100	Immunohistochemical screening for oncogenic tyrosine kinase activation. Journal of Pathology, 1999, 187, 588-593.	4.5	1
101	Immunohistochemistry of Bone-Marrow Biopsy. Leukemia and Lymphoma, 1997, 26, 69-75.	1.3	11
102	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. Journal of Pathology, 1997, 183, 116-123.	4.5	244
103	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. Journal of Pathology, 1997, 183, 116-123.	4.5	179
104	Bone Marrow Findings Further Support the Hypothesis that Essential Mixed Cryoglobulinemia Type II is Characterized by a Monoclonal B-Cell Proliferation. Leukemia and Lymphoma, 1995, 20, 119-124.	1.3	55